Prelude Therapeutics Incorporated Common Stock (PRLD)
Stock · NASDAQ · Health Care
$3.26as of 10/16/2026
Price chart
Active signals
PRLD Signal Track Record
How signals performed across all stocks →What PRLD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -0.3% | 49% | September 18, 2026 |
| Bollinger Band Breakout | 30 | +5.4% | 67% | August 11, 2026 |
| Bollinger Band Breakdown | 20 | +9.3% | 55% | June 2, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -6.9% | 23% | October 8, 2026 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and othe…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 79
- Website
- preludetx.com/
Fundamentals
- 1-day range
- $3.3$3.5
- Market cap
- $372.74M
- P/E (trailing)
- —
- P/E (forward)
- -6.11
- EPS (trailing)
- $-0.73
- Dividend yield
- —
- Beta
- 1.18
- Avg. volume
- 479.1K
How Prelude Therapeutics Incorporated Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Prelude Therapeutics Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- PRLDPrelude Therapeutics Incorporated Common Stock$3.26▼ 1.81%Market cap $372.74MP/E —$1.16$6.83
- UPBUpstream Bio Inc. Common Stock$2.76▼ 18.10%Market cap $373.87MP/E —$3.29$33.68
- DMACDiaMedica Therapeutics Inc. Common Stock$7.57▼ 5.85%Market cap $364.79MP/E —$5.25$10.42
- RCKTRocket Pharmaceuticals Inc. Common Stock$2.18▼ 7.63%Market cap $386.55MP/E —$2.42$5.45
- NATRNature's Sunshine Products Inc. Common Stock$12.64▲ 0.00%Market cap $357.68MP/E 12.66$12.8$28.14
- ENTAEnanta Pharmaceuticals Inc. Common Stock$11.1▼ 3.23%Market cap $387.91MP/E —$10.2$17.15
- ZNTLZentalis Pharmaceuticals Inc. Common Stock$2.13▼ 4.91%Market cap $355.93MP/E —$1.21$6.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PRLD Prelude Therapeutics Incorporated Common Stock | $372.74M | — | $3.26 | ▼ 1.81% | $1.16$6.83 |
| UPB Upstream Bio Inc. Common Stock | $373.87M | — | $2.76 | ▼ 18.10% | $3.29$33.68 |
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $7.57 | ▼ 5.85% | $5.25$10.42 |
| RCKT Rocket Pharmaceuticals Inc. Common Stock | $386.55M | — | $2.18 | ▼ 7.63% | $2.42$5.45 |
| NATR Nature's Sunshine Products Inc. Common Stock | $357.68M | 12.66 | $12.64 | ▲ 0.00% | $12.8$28.14 |
| ENTA Enanta Pharmaceuticals Inc. Common Stock | $387.91M | — | $11.1 | ▼ 3.23% | $10.2$17.15 |
| ZNTL Zentalis Pharmaceuticals Inc. Common Stock | $355.93M | — | $2.13 | ▼ 4.91% | $1.21$6.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Victor Sandor · June 9, 2026 · Grant38.0K
- Dorton Katina · June 9, 2026 · Grant38.0K
- David P. Bonita · June 9, 2026 · Grant38.0K
- Babler Martin · June 9, 2026 · Grant38.0K
- Paul A. Friedman · June 9, 2026 · Grant38.0K
- BAKER JULIAN · June 9, 2026 · Grant38.0K
- Morris Charles Q · May 1, 2026 · Grant450.0K @ $4.7
- RA Capital Healthcare Fund LP · April 27, 2026 · J1.41M
- David P. Bonita · April 21, 2026 · Buy1.13M @ $4.44
- David P. Bonita · April 21, 2026 · Buy1.69M @ $4.44
- ORBIMED ADVISORS LLC · April 21, 2026 · Buy1.13M @ $4.44
- ORBIMED ADVISORS LLC · April 21, 2026 · Buy1.69M @ $4.44
- BAKER JULIAN · April 21, 2026 · Buy2.14M @ $4.44
- BAKER JULIAN · April 21, 2026 · Buy114.6K @ $4.44
Institutional Ownership
March 31, 2026
- Total shares held
- 30.63M
- Total value held
- $102.81M
- Institutional holders
- 52
- Unknown10.91M
- Unknown10.12M
- Unknown1.59M
- Unknown1.23M
- Unknown947.0K
- Unknown923.6K
- Unknown558.3K
- Unknown511.5K
- Unknown382.7K
- Unknown358.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PRLD announces collaboration and supply deal with Eli Lilly
Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.
PRLD announces collaboration and supply deal with Eli Lilly. Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.